急性呼吸窘迫综合征相关肺纤维化的研究进展  

Research progress in acute respiratory distress syndrome related pulmonary fibrosis

作　　者：田学 谢晖[1] 王瑞兰[1] Tian Xue;Xie Hui;Wang Ruilan(Department of Critical Care Medicine,Shanghai General Hospital of Nanjing Medical University,Shanghai Jiaotong University,School of Medicine,Shanghai 201620,China)

机构地区：[1]南京医科大学附属上海一院临床医学院,上海交通大学附属第一人民医院急诊危重病科,上海201620

出　　处：《中华重症医学电子杂志》2024年第3期258-264,共7页Chinese Journal Of Critical Care & Intensive Care Medicine(Electronic Edition)

基　　金：国家自然科学基金面上项目(82072210);上海申康医院发展中心临床三年行动计划资助项目(SHDC2020CR2013A,SHDC2020CR5010-003)

摘　　要：急性呼吸窘迫综合征(ARDS)是以弥漫性肺泡损伤(DAD)为特征的难治性低氧血症,其并发的肺纤维化常常引起高病死率,在重症新型冠状病毒感染(COVID-19)患者中尤为突出。ARDS异质性高,现阶段研究热点聚焦于ARDS亚表型的精准治疗,而纤维增生性ARDS机制复杂,且缺乏应用于临床的诊断性标志物而增加治疗难度以及难以评估预后。本文就ARDS相关肺纤维化发病机制以及研究进展进行综述。Acute respiratory distress syndrome(ARDS)is refractory hypoxemia characterized by diffuse alveolar injury.As a complication,pulmonary fibrosis often leads to high mortality,especially in severe COVID-19.The heterogeneity of ARDS is prominent.Current researches focus on precise treatment for subtypes of ARDS.However,mechanism of fibroproliferative ARDS is complex,lack of diagnostic biomarkers for clinical application,which increases the difficulty of treatment and predicting prognosis.This article reviews research progress of pulmonary fibrosis pathogenesis in ARDS.

关 键 词：急性呼吸窘迫综合征 肺纤维化 新型冠状病毒感染 

分 类 号：R563.8[医药卫生—呼吸系统] R563.9[医药卫生—内科学]